Menu
Innovation Observatory > Reports > Drugs > Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults

< Back

Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults

Drugs

Neurology and Neurosurgery

June 2017


A pharmaceutical formulation of the cannabis extract, cannabidiol is being developed for those patients who do not respond to previous treatments for seizures associated with Lennox-Gastaut syndrome. This is taken as an oral solution.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts